Matt Susko, MD
Radiology • Radiation Oncology
Matt Susko, MD
Radiology • Radiation OncologyOn this page
About me
Dr. Matt Susko is a radiation oncologist specializing in brain, spine and eye tumors. He also uses palliative radiation to reduce symptoms from late-stage cancers. He has expertise in many advanced techniques, including stereotatic radiosurgery (SRS), stereotactic body radiotherapy (SBRT) and proton therapy.
Susko earned his medical degree at Duke University School of Medicine. He completed a residency in radiation oncology at UCSF. He also earned a master's degree in global health sciences from UCSF.
Education
Board Certification
- Radiation Oncology, American Board of Radiology
Residency
- Radiation Oncology, UCSF School of Medicine -GME
Internship
- Internal Medicine, Kaiser Foundation Hospital - Oakland
School
- MD, Duke University School of Medicine
Academic Title
- Clinical Professor
Care Keywords
Services
- Radiology
- Radiation Oncology
Conditions
- Brain and Spine Tumors
- Sarcoma
- Central Nervous System Malignancy
- Eye Cancer
Treatments
- Total Body Irradiation
- Volumetric Modulated Arc Therapy
- Stereotactic Cranial Radiation
- Stereotactic Spine Radiosurgery
- Gamma Knife Radiosurgery
- Three-Dimensional Conformal Radiation Therapy
- Stereotactic Radiosurgery
- Stereotactic Ablative Radiotherapy
- Intensity-Modulated Radiation Therapy
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%222916%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=start_date_dt+asc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%222916%22%29&rows=4&sort=date_published+asc&fq=content_type%3A%22Publication%22
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.